Stock Movers Cidara Therapeutics Rises, Stubhub Sinks, Warner Brothers-Discovery Rises on News of Auction
Nov 14, 2025
Merck is making headlines with its $9.2 billion tender offer to acquire Cidara Therapeutics, aiming to boost its portfolio before major patent expirations. Meanwhile, Stubhub's stock plummets by 31% after failing to provide a quarterly forecast, leaving investors in shock. On a brighter note, Warner Bros. Discovery's shares soar amid reports of an auction attracting bids from major players like Paramount, Comcast, and Netflix, signaling significant interest in the media giant's future.
AI Snips
Chapters
Transcript
Episode notes
Merck Buys Cidara To Shore Up Pipeline
- Merck agreed to buy Cidara Therapeutics for $221.50 a share, valuing the deal at about $9.2 billion.
- Merck is pursuing acquisitions to offset projected patent-led revenue losses, including Keytruda expirations.
Patent Cliff Drives Aggressive M&A
- Merck expects about $18 billion of sales erosion over five years from patent expirations like Keytruda in 2028.
- The company is expanding its respiratory and therapeutic portfolio through deals like Verona Pharma and now Cidara.
No Guidance Sparks StubHub Selloff
- StubHub beat Q2 revenue estimates but declined sharply after refusing to provide current-quarter guidance.
- Management cited variable ticket sale timing and will only offer 2026 outlook when Q4 results are reported.